Universidad Bernardo O´Higgins, Escuela de Nutrición y Dietética, Facultad de Ciencias de la Salud. Santiago, Chile
Universidad Arturo Prat. Iquique, Chile
Universidad Bernardo O´Higgins, Escuela de Nutrición y Dietética, Facultad de Ciencias de la Salud. Santiago, Chile
Integramédica, parte de BUPA, director médico ITR-IBB-ITA.Santiago, Chile
Universidad Andrés Bello, Laboratorio de Microbiología y Biotecnología Oral, Facultad de Ciencias de la Vida. Santiago, Chile
Fundación Oncoloop. Santiago, Chile
Universidad Católica de la Santísima Concepción, Facultad de Medicina. Concepción, Chile
Introduction: Ulcerative colitis is a disease whose causes are multifactorial. Current therapies, such as monoclonal antibodies, present risks, prompting the search for non-pharmacological alternatives such as intermittent fasting. To detect inflammatory conditions, the levels of calprotectin and C-reactive protein are measured.
Objective: To evaluate the effects of intermittent fasting in a 34-year-old patient with ulcerative colitis, on the inflammatory markers calprotectin and C-reactive protein (CRP).
Clinical case: 34-year-old Caucasian woman diagnosed with ulcerative colitis in remission, she participated in an 8-week pilot study on intermittent fasting. After the intervention, it was observed that there were no significant changes in her PRC levels, however, calprotectin increased from 15 mg/kg to 1279 mg/kg, indicating an inflammatory bowel condition in the initial stage given that the patient was asymptomatic.
Conclusions: Calprotectin determination is a more appropriate marker to identify intestinal inflammation in early stages. Intermittent fasting could be a complementary therapeutic strategy to extend the periods of symptom remission in this disease.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.